May 23, 2022

Volume XII, Number 143

Advertisement
Advertisement

May 20, 2022

Subscribe to Latest Legal News and Analysis
Advertisement

Study Suggests Skin Cancer Drug May Help Treat Mesothelioma and Lung Cancers

In the world of cancer treatment, chemotherapy and radiation have historically reigned supreme. Recently, however, researchers have added immunotherapy, which has fewer side effects. One immunotherapy drug, Pembrolizumab, marketed as Keytruda, was approved by the FDA in 2014 for the treatment of a rare form of skin cancer. Since then, researchers have been testing the drug on various other cancers, and recent studies indicate it may prove beneficial in the treatment of both mesothelioma and lung cancer.

Just last month, the University of Pennsylvania School of Medicine released new research indicating that Keytruda may slow or even reverse the growth of mesothelioma tumors. After traditional chemotherapy was unsuccessful, 25 participants in an initial study received Keytruda as a second line treatment.  Twelve of the 25 experienced no tumor growth, and another seven actually reported tumor shrinkage. Only four of the original 25 reported tumor growth. The remaining two were not assessed. Meanwhile, a separate study reported that the drug stopped lung cancer growth in 19 percent of 495 patients.

The drug shows considerable promise and will be tested in a phase II clinical trial for the treatment of malignant mesothelioma at the University of Chicago Medical Center. The study is expected to conclude in March 2018.

© Steptoe & Johnson PLLC. All Rights Reserved.National Law Review, Volume V, Number 126
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Jim Mulhall, Litigation Attorney, Steptoe Johnson Law FIrm
Member

Jim Mulhall is the leader of the firm's Products Liability Practice Group and Toxic Torts Team.  Mr. Mulhall concentrates his practice in the areas of asbestos, product liability, toxic torts, and mass tort litigation.  He is the co-chair of the International Dispute Resolution Practice Group in TerraLex.

(304) 933-8164
Advertisement
Advertisement
Advertisement